Centre for Lymphoid Cancer, BC Cancer Agency, Vancouver, British Columbia, Canada.
Département de bio-pathologie, Institut Paoli-Calmettes, Marseille, France.
Clin Cancer Res. 2015 Aug 1;21(15):3428-35. doi: 10.1158/1078-0432.CCR-14-3253. Epub 2015 Apr 13.
We aimed to assess the prognostic significance of follicular lymphoma-associated macrophages in the era of rituximab treatment and maintenance.
We applied immunohistochemistry for CD68 and CD163 to two large tissue microarrays (TMA). The first TMA included samples from 186 patients from the BC Cancer Agency (BCCA) who had been treated with first-line systemic treatment including rituximab, cyclophosphamide, vincristine, and prednisone. The second contained 395 samples from PRIMA trial patients treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone, and randomized to rituximab maintenance or observation. Macrophage infiltration was assessed using Aperio image analysis. Each of the two cohorts was randomly split into training/validation sets.
An increased CD163-positive pixel count was predictive of adverse outcome in the BCCA dataset [5-year progression-free survival (PFS) 38% vs. 72%, respectively, P = 0.004 in the training cohort and 5-year PFS 29% vs. 61%, respectively, P = 0.004 in the validation cohort]. In the PRIMA trial, an increased CD163 pixel count was associated with favorable outcome (5-year PFS 60% vs. 44%, respectively, P = 0.011 in the training cohort and 5-year PFS 55% vs. 37%, respectively, P = 0.030 in the validation cohort).
CD163-positive macrophages predict outcome in follicular lymphoma, but their prognostic impact is highly dependent on treatment received.
我们旨在评估滤泡性淋巴瘤相关巨噬细胞在利妥昔单抗治疗和维持时代的预后意义。
我们应用 CD68 和 CD163 的免疫组织化学方法对两个大型组织微阵列（TMA）进行了分析。第一个 TMA 包含了来自 BC 癌症机构（BCCA）的 186 名患者的样本，这些患者接受了包括利妥昔单抗、环磷酰胺、长春新碱和泼尼松在内的一线系统治疗。第二个 TMA 包含了来自 PRIMA 试验的 395 名患者的样本，这些患者接受了利妥昔单抗、环磷酰胺、多柔比星、长春新碱和泼尼松的治疗，并随机分配到利妥昔单抗维持或观察组。巨噬细胞浸润情况使用 Aperio 图像分析进行评估。两个队列中的每一个都随机分为训练/验证集。
CD163 阳性像素计数的增加与 BCCA 数据集的不良结局相关[训练队列的 5 年无进展生存（PFS）分别为 38%和 72%，P = 0.004；验证队列的 5 年 PFS 分别为 29%和 61%，P = 0.004]。在 PRIMA 试验中，CD163 像素计数的增加与良好的结局相关[训练队列的 5 年 PFS 分别为 60%和 44%，P = 0.011；验证队列的 5 年 PFS 分别为 55%和 37%，P = 0.030]。
CD163 阳性巨噬细胞可预测滤泡性淋巴瘤的结局，但它们的预后影响高度依赖于所接受的治疗。
